Expert perspectives on the management of myeloproliferative neoplasms (MPNs) from a virtual tumor board discussion. The segments cover treatment approaches, including the use of JAK inhibitors, and key efficacy and safety data from clinical trials that inform treatment selection.
EP. 1: Treatment Approaches for Myeloproliferative Neoplasms
May 6th 2024This segment discusses the current classification of myeloproliferative neoplasms (MPNs) and the pathogenesis of these disorders, particularly the role of the JAK-STAT signaling pathway. It also presents a treatment algorithm for higher-risk myelofibrosis, with a focus on the use of JAK inhibitors such as ruxolitinib, fedratinib, pacritinib, and momelotinib.
Watch